FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996237660> ?p ?o ?g. }

• W2996237660 endingPage "180.e8" @default.
• W2996237660 startingPage "180.e1" @default.
• W2996237660 abstract "The standard recommended treatment for neurogenic detrusor overactivity (NDO) is clean intermittent catheterization combined with an antimuscarinic agent. However, the adverse systemic side-effects of oxybutynin, the most widely used agent, are of concern.To evaluate the efficacy and safety of solifenacin in pediatric patients with NDO, aged 6 months-<5 years and 5-<18 years.Two open-label, baseline-controlled, phase 3 studies were conducted in pediatric patients with NDO. Patients were treated with sequential doses of solifenacin oral suspension (pediatric equivalent doses 2.5-10 mg) for 12 weeks to determine each patient's optimal dose, followed by a fixed dose ≥40-week treatment period. Primary efficacy endpoint was change from baseline in maximum cystometric capacity (MCC) after 24 weeks. Secondary endpoints included bladder compliance, bladder volume until first detrusor contraction (>15 cmH2O), number of overactive detrusor contractions (>15 cmH2O), maximum catheterized volume (MCV)/24 h, and incontinence episodes/24 h. Safety parameters were treatment-emergent adverse events (TEAEs), serious adverse events, laboratory variables, vital signs, electrocardiograms, and ocular accommodation and cognitive function assessments.After 24 weeks, MCC had significantly increased compared with baseline in patients aged 6 months -<5 years and 5-<18 years (37.0 ml and 57.2 ml, respectively; P < 0.001; Fig.). Improvement was also observed after 52 weeks' treatment. Significant changes were observed from baseline to week 24 in all secondary endpoints in both age groups: increase in bladder compliance, increase in bladder volume to first detrusor contraction as a percentage of expected bladder capacity, reduction in the number of overactive detrusor contractions, increase in MCV, and decreased incontinence episodes. TEAEs were mostly mild or moderate, and there were no new drug-related TEAEs compared with adult studies. Age-related improvements were noted in ocular accommodation and cognitive function.These long-term multicenter investigations demonstrated the efficacy and safety of solifenacin in pediatric patients with NDO. The observed increases in MCC were clinically relevant and demonstrated that an increase in fluid volume can be accommodated in the bladder prior to reaching intravesical pressures that endanger kidney function and/or are associated with leakage or discomfort. Solifenacin was well tolerated with low incidences of constipation and dry mouth (typically associated with antimuscarinics), central nervous system-related side-effects, and facial flushing.Solifenacin was effective and well tolerated in pediatric patients with NDO, aged 6 months-<18 years, suggesting that it is a viable alternative to oxybutynin, the current standard of care. STUDIES ARE REGISTERED AT CLINICALTRIALS.GOV: NCT01981954 and NCT01565694." @default.
• W2996237660 created "2019-12-26" @default.
• W2996237660 creator A5006418138 @default.
• W2996237660 creator A5008722654 @default.
• W2996237660 creator A5008809342 @default.
• W2996237660 creator A5022047928 @default.
• W2996237660 creator A5027451751 @default.
• W2996237660 creator A5030669093 @default.
• W2996237660 creator A5039718407 @default.
• W2996237660 creator A5054531832 @default.
• W2996237660 creator A5061152501 @default.
• W2996237660 creator A5067021686 @default.
• W2996237660 creator A5070559261 @default.
• W2996237660 creator A5086289312 @default.
• W2996237660 date "2020-04-01" @default.
• W2996237660 modified "2023-10-03" @default.
• W2996237660 title "Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies" @default.
• W2996237660 cites W1955418933 @default.
• W2996237660 cites W1969740456 @default.
• W2996237660 cites W1973736267 @default.
• W2996237660 cites W1990227511 @default.
• W2996237660 cites W1994316443 @default.
• W2996237660 cites W2018255501 @default.
• W2996237660 cites W2024557546 @default.
• W2996237660 cites W2038092217 @default.
• W2996237660 cites W2044969863 @default.
• W2996237660 cites W2066632753 @default.
• W2996237660 cites W2080859925 @default.
• W2996237660 cites W2081060951 @default.
• W2996237660 cites W2083580221 @default.
• W2996237660 cites W2092473900 @default.
• W2996237660 cites W2097407437 @default.
• W2996237660 cites W2122751872 @default.
• W2996237660 cites W2130124185 @default.
• W2996237660 cites W2144142002 @default.
• W2996237660 cites W2168699550 @default.
• W2996237660 cites W2170255628 @default.
• W2996237660 cites W2179853945 @default.
• W2996237660 cites W2233327055 @default.
• W2996237660 cites W2421061985 @default.
• W2996237660 cites W2526505218 @default.
• W2996237660 cites W2612640894 @default.
• W2996237660 cites W3196797181 @default.
• W2996237660 cites W4237933372 @default.
• W2996237660 doi "https://doi.org/10.1016/j.jpurol.2019.12.012" @default.
• W2996237660 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32007426" @default.
• W2996237660 hasPublicationYear "2020" @default.
• W2996237660 type Work @default.
• W2996237660 sameAs 2996237660 @default.
• W2996237660 citedByCount "11" @default.
• W2996237660 countsByYear W29962376602020 @default.
• W2996237660 countsByYear W29962376602021 @default.
• W2996237660 countsByYear W29962376602023 @default.
• W2996237660 crossrefType "journal-article" @default.
• W2996237660 hasAuthorship W2996237660A5006418138 @default.
• W2996237660 hasAuthorship W2996237660A5008722654 @default.
• W2996237660 hasAuthorship W2996237660A5008809342 @default.
• W2996237660 hasAuthorship W2996237660A5022047928 @default.
• W2996237660 hasAuthorship W2996237660A5027451751 @default.
• W2996237660 hasAuthorship W2996237660A5030669093 @default.
• W2996237660 hasAuthorship W2996237660A5039718407 @default.
• W2996237660 hasAuthorship W2996237660A5054531832 @default.
• W2996237660 hasAuthorship W2996237660A5061152501 @default.
• W2996237660 hasAuthorship W2996237660A5067021686 @default.
• W2996237660 hasAuthorship W2996237660A5070559261 @default.
• W2996237660 hasAuthorship W2996237660A5086289312 @default.
• W2996237660 hasBestOaLocation W29962376601 @default.
• W2996237660 hasConcept C126322002 @default.
• W2996237660 hasConcept C126894567 @default.
• W2996237660 hasConcept C142724271 @default.
• W2996237660 hasConcept C197934379 @default.
• W2996237660 hasConcept C203092338 @default.
• W2996237660 hasConcept C204787440 @default.
• W2996237660 hasConcept C2777844464 @default.
• W2996237660 hasConcept C2778941218 @default.
• W2996237660 hasConcept C2779502394 @default.
• W2996237660 hasConcept C42219234 @default.
• W2996237660 hasConcept C535046627 @default.
• W2996237660 hasConcept C71924100 @default.
• W2996237660 hasConceptScore W2996237660C126322002 @default.
• W2996237660 hasConceptScore W2996237660C126894567 @default.
• W2996237660 hasConceptScore W2996237660C142724271 @default.
• W2996237660 hasConceptScore W2996237660C197934379 @default.
• W2996237660 hasConceptScore W2996237660C203092338 @default.
• W2996237660 hasConceptScore W2996237660C204787440 @default.
• W2996237660 hasConceptScore W2996237660C2777844464 @default.
• W2996237660 hasConceptScore W2996237660C2778941218 @default.
• W2996237660 hasConceptScore W2996237660C2779502394 @default.
• W2996237660 hasConceptScore W2996237660C42219234 @default.
• W2996237660 hasConceptScore W2996237660C535046627 @default.
• W2996237660 hasConceptScore W2996237660C71924100 @default.
• W2996237660 hasFunder F4320323599 @default.
• W2996237660 hasFunder F4320332563 @default.
• W2996237660 hasIssue "2" @default.
• W2996237660 hasLocation W29962376601 @default.
• W2996237660 hasLocation W29962376602 @default.
• W2996237660 hasLocation W29962376603 @default.
• W2996237660 hasOpenAccess W2996237660 @default.

• next